In fact, patients suitable for anti-EGFR, anti-VEGF, or immunotherapy only comprise of small portion of patients with CRC, whereas our results indicate significantly higher expression of HFG in most CRC tumor tissue than in normal tissue. This evidence concerns the gene EGFR and colorectal carcinoma.